Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
UCLA Clinical Genomics Center, |
RCV000198029 | SCV000255414 | pathogenic | Charcot-Marie-Tooth disease type 2I; Charcot-Marie-Tooth disease type 2J; Charcot-Marie-Tooth disease type 1B; Charcot-Marie-Tooth disease dominant intermediate D; Roussy-Lévy syndrome; Dejerine-Sottas disease; Charcot-Marie-Tooth disease type 4E | 2014-03-11 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001851867 | SCV002212021 | pathogenic | Charcot-Marie-Tooth disease, type I | 2020-12-19 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this variant affects MPZ protein function (PMID: 29687021). This missense change has been observed in individual(s) with Dejerine-Sottas disease (PMID: 7506095, 10399750, 12242557). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 14170). This variant is also known as p.Gly138Arg in the literature. This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with arginine at codon 167 of the MPZ protein (p.Gly167Arg). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and arginine. |
OMIM | RCV000015233 | SCV000035492 | pathogenic | DEJERINE-SOTTAS SYNDROME, AUTOSOMAL DOMINANT | 1993-11-01 | no assertion criteria provided | literature only | |
Gene |
RCV000032123 | SCV000055676 | pathologic | Dejerine-Sottas disease | 2012-10-18 | no assertion criteria provided | curation | Converted during submission to Pathogenic. |
Inherited Neuropathy Consortium | RCV000032123 | SCV000928794 | uncertain significance | Dejerine-Sottas disease | no assertion criteria provided | literature only |